



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

30<sup>th</sup> May 2024

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
**Mumbai 400 001**

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Please find enclosed herewith the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Thanking you,

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

**Ref: PR/03/2024-25**

**30<sup>th</sup> May, 2024**

### **Update**

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces submission of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with the U.S. Food and Drug Administration (FDA) for the generic version of Rimegepant Sulfate tablet Eq 75mg base strength. Rimegepant is currently indicated for the acute treatment of migraine with or without aura in adults and for the preventive treatment of episodic migraine in adults. Rimegepant Sulfate tablets are marketed in the United States (US) by Pfizer Inc. under the brand name NURTEC ODT®. Natco has been named as defendant in a lawsuit filed in the United States district court for the district of Delaware by Pfizer Inc. and Pfizer Ireland pharmaceuticals. We believe that our ANDA may be eligible for 180 days of marketing exclusivity at the time of potential launch of the product under certain circumstances.

NURTEC ODT® has recorded sales of USD 908 million in the US market for the year ending December 2023, as per Pfizer financial results presentation.

---

For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer